Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ova...

Date 14 September 2018
Event MAP 2018 - Molecular Analysis for Personalised Therapy
Session Precision medicine in gynaecological cancers and its implication outside the field
Topics Ovarian Cancer
Presenter Evgeny Imyanitov
Citation Annals of Oncology (2018) 29 (ersion="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publi
Authors E. Imyanitov1, E. Savonevich2, A. Ivantsov1, T. Gorodnova3, E. Preobrazhenskaya1, M. Kleshchov1, E.S. Kuligina1, A. Sokolenko1
  • 1Department Of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU
  • 2Grodno State Medical University, 230023 - Grodno/BY
  • 3Department Of Gynecology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU


Cancers arising in BRCA1 mutation carriers are highly sensitive to cisplatin due to somatic inactivation of the wild-type BRCA1 allele. Accordingly, BRCA1-driven OCs usually respond well to NACT and therefore almost always undergo complete cytoreduction. However, despite this seemingly effective treatment and continuation of platinum therapy in the adjuvant setting, almost all BRCA1-associated OCs inevitably relapse.